EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Safety‐Related Drug Label Changes Following Large Post‐Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports

Viktoriia Starokozhko, Fatima Tarrahi, Patrick J W S Vrijlandt, Peter G M Mol

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2840 ↗

At a glance

Übersichtsarbeit in Clinical Pharmacology & Therapeutics, 2023. Written by Viktoriia Starokozhko and 3 co-authors. Institution: Dutch Medicines Evaluation Board, Utrecht, The Netherlands. Major MEDLINE topics: Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases. Cited 2 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Selective safety data collection may simplify late‐stage clinical trials and improve their feasibility. However, the impact on increasing overall drug safety knowledge is unknown. The aim of this study is to evaluate how much safety information is added to the drug label based on large trials after initial authorization. Changes made to the “undesirable effects” section of the drug label of cardiometabolic agents approved between 2000 and 2020 based on the results of large (> 1,000 patient) clinical trials submitted to the European Medicines Agency (EMA) were evaluated. The study focused on glucose lowering, antithrombotic, and lipid‐modifying agents. The primary outcome was the number of changes in adverse drug reactions in the drug label. The EMA reviewed 55 large trials concerning 25 cardiometabolic agents after the initial marketing authorization, which included 402,444 patients. Ultimately, 38 trials (69%) resulted in a safety section update, whereas 17 trials (31%) did not. Changes in listed adverse drug reactions were made following 19 trials (35%) for 12 agents: 77 adverse drug reactions were added, 11 were deleted, and the frequencies of 43 were changed. Most changes in adverse drug reactions arose from trials with antithrombotic agents (88%) and trials performed in a new population (92%). Large trials for cardiometabolic agents reported after authorization add limited new safety information on adverse drug reactions, especially when performed in the population studied prior to approval. This suggests that selective safety data collection does not reduce learnings from late stage cardiometabolic trials in populations comprehensively studied before.

Subjects

MeSH terms (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsCardiovascular DiseasesHumansMarketingDrug LabelingDrug Approval

Authors and institutions

  • Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Scientific Advice Working Party, European Medicines Agency (EMA), Amsterdam, The Netherlands.

Cite

APA

Starokozhko, V., Tarrahi, F., Vrijlandt, P. J. W. S., & Mol, P. G. M. (2023). Safety‐Related Drug Label Changes Following Large Post‐Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2840

Vancouver

Starokozhko V, Tarrahi F, Vrijlandt PJWS, Mol PGM. Safety‐Related Drug Label Changes Following Large Post‐Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2840

BibTeX
@article{Starokozhko2023,
  author = {Starokozhko, Viktoriia and Tarrahi, Fatima and Vrijlandt, Patrick J W S and Mol, Peter G M},
  title = {Safety‐Related Drug Label Changes Following Large Post‐Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2840}
}
Start for free →